The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_005214.5:c.563A>G

CA2067131

4683122 (ClinVar)

Gene: CTLA4 (HGNC:1493)
Condition: autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency (MONDO:0014493)
Inheritance Mode: Autosomal dominant inheritance
UUID: a0b3a8d5-92e4-4678-a5f0-1e6bc6e1162f
Approved on: 2026-09-14
Published on: 2026-09-14

HGVS expressions

NM_005214.5:c.563A>G
NC_000002.12:g.203871483A>G
CM000664.2:g.203871483A>G
NC_000002.11:g.204736206A>G
CM000664.1:g.204736206A>G
NC_000002.10:g.204444451A>G
NG_011502.1:g.8698A>G
ENST00000696049.1:c.507+56A>G
ENST00000696479.1:c.635A>G
ENST00000427473.3:n.491+550A>G
ENST00000648405.2:c.563A>G
ENST00000650075.1:n.587A>G
ENST00000295854.10:c.457+550A>G
ENST00000302823.7:c.563A>G
ENST00000427473.2:c.346+550A>G
ENST00000472206.1:c.172+835A>G
ENST00000487393.1:n.110-1225A>G
NM_001037631.2:c.457+550A>G
NM_005214.4:c.563A>G
NM_001037631.3:c.457+550A>G
More

Benign

Met criteria codes 1
BA1
Not Met criteria codes 2
PP3 BP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Antibody Deficiencies Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for CTLA4 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Antibody Deficiencies VCEP
NM_005214.5(CTLA4):c.563A>G (p.Lys188Arg) is a missense variant encoding substitution of lysine by arginine at residue 188. This variant is present in gnomAD v4.1.1 at a GrpMax allele frequency of 0.0001370, with 11 alleles / 44,874 total alleles in the East Asian population, which is higher than the ClinGen Antibody Deficiencies VCEP BA1 threshold of >0.0000111 (BA1). The computational predictor REVEL gives a score of 0.035, which is below the ClinGen Antibody Deficiencies VCEP threshold of <0.290, while the computational predictor CADD gives a PHRED score of 20.3, which is below the ClinGen Antibody Deficiencies VCEP threshold of <22.7, with both predictors agreeing on a non-deleterious effect on CTLA4 function. The splicing impact predictor SpliceAI gives a delta score of 0.10 for donor loss and donor gain, which is above the ClinGen Antibody Deficiencies VCEP recommended BP4 threshold of <0.1 yet does not strongly predict an impact on CTLA4 splicing. In summary, this variant meets the criteria to be classified as Benign for autosomal dominant autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Antibody Deficiencies VCEP: BA1. (VCEP specifications version 2.0.0).
Met criteria codes
BA1
This variant is present in gnomAD v4.1.0 at a GrpMax allele frequency of 0.0001370, with 11 alleles / 44,874 total alleles] in the East Asian population, which is higher than the ClinGen Antibody Deficiencies VCEP BA1 threshold of >0.0000111 (BA1).
Not Met criteria codes
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
The computational predictor REVEL gives a score of 0.035, which is below the ClinGen Antibody Deficiencies VCEP threshold of <0.290, while the computational predictor CADD gives a PHRED score of 20.3, which is below the ClinGen Antibody Deficiencies VCEP threshold of <22.7, with both predictors agreeing on a non-deleterious effect on CTLA4 function. The splicing impact predictor SpliceAI gives a delta score of 0.10 for donor loss and donor gain, which is above the ClinGen Antibody Deficiencies VCEP recommended threshold of <0.1 and does not strongly predict an impact on CTLA4 splicing.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.